Historique
Rapport
CUMYL-4CN-BINACA. Report on the risk assessment of 1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (CUMYL-4CN-BINACA) in the framework of the Council Decision on new psychoactive substances
Auteur(s) :
OEDT = EMCDDA (Observatoire européen des drogues et des dépendances = European monitoring centre for drugs and drug addiction)
Année
2018
Page(s) :
60 p.
Langue(s) :
Anglais
Collection :
Risk assessments, 23
Domaine :
Drogues illicites / Illicit drugs
Discipline :
PRO (Produits, mode d'action, méthode de dépistage / Substances, action mode, screening methods)
Organismes
OEDT
Thésaurus mots-clés
CANNABINOIDES
;
CONTROLE DES STUPEFIANTS
;
FACTEUR DE RISQUE
;
DROGUES DE SYNTHESE
;
PHARMACOLOGIE
;
TYPE D'USAGE
;
EFFET SECONDAIRE
;
TOXICITE
;
INTOXICATION
;
MORTALITE
;
SURVEILLANCE EPIDEMIOLOGIQUE
Thésaurus géographique
EUROPE
Note de contenu :
TABLE OF CONTENTS:
- Foreword.
- EMCDDA actions on monitoring and responding to new drugs.
- Europol-EMCDDA Joint Report on CUMYL-4CN-BINACA (1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide) - a summary.
- Risk Assessment Report on a new psychoactive substance: 1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (CUMYL-4CN-BINACA).
- Technical report on 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (CUMYL-4CN-BINACA).
- Participants of the risk assessment meeting, 7-8 November 2017.
- Foreword.
- EMCDDA actions on monitoring and responding to new drugs.
- Europol-EMCDDA Joint Report on CUMYL-4CN-BINACA (1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide) - a summary.
- Risk Assessment Report on a new psychoactive substance: 1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (CUMYL-4CN-BINACA).
- Technical report on 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (CUMYL-4CN-BINACA).
- Participants of the risk assessment meeting, 7-8 November 2017.
Résumé :
This publication presents the data and findings of the risk assessment on 1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (CUMYL-4CN-BINACA), carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2017. On the basis of the Risk Assessment Report - and on the initiative of the European Commission - on 14 May 2018, the Council decided that CUMYL-4CN-BINACA should be subject to control measures across the Member States.